NHS England updates CDF List
NHS England updates CDF List
NHS England has updated the Cancer Drugs Fund List. The latest version (v1.341) was uploaded to the NHS England Website on Friday 3, January 2025.
The following changes have been introduced:
Crizotinib (CRI3)
1st or subsequent line systemic therapy for ROS1-positive inoperable locally advanced/metastatic non squamous non- small cell lung cancer where the following criteria have been met
Moved into routine commissioning - section B of list
Trifluridine plus tipiracil in combination with bevacizumab (TRI3)
For patients with either metastatic or locally advanced and inoperable colorectal cancer who have received 2 or more prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies with without anti-VEGF agents and/or anti- EGFR-based agents where the following criteria have been met
Moved into routine commissioning - section B of list
Durvalumab in combination with chemotherapy (DUR3)
For the treatment of neoadjuvant treatment and then continued as adjuvant monotherapy in adults with previously untreated UICC/AJCC 8th edition stage IIA or IIB or IIIA or N2 only IIIB non-small cell lung cancer AND who are candidates for potentially curative surgery where the following criteria have been met
Treatment criterion (#18) updated
Ivosidenib in combination with azacitidine (IVO2)
For newly diagnosed and untreated adult acute myeloid leukaemia with an isocitrate dehydrogenease-1 (IDH1) R132 mutation in patients who are not eligible for standard induction chemotherapy where the following criteria have been met
Treatment criterion (#10) updated
Pembrolizumab (PEMB30)
Pembrolizumab in combination with chemotherapy for neoadjuvant treatment and then continued as adjuvant monotherapy in adults with previously untreated UICC/AJCC 8th edition stage IIA or IIB or IIIA or N2 only IIIB non-small cell lung cancer AND who are candidates for potentially curative surgery where the following criteria have been met
Treatment criterion (#19) updated
Venetoclax in combination with azacitidine (VEN8)
For untreated adult acute myeloid leukaemia in patients unsuitable for intensive chemotherapy where the following criteria have been met
Treatment criterion (#10) updated
Venetoclax in combination with low dose cytarabine (VEN9)
For previously untreated adult acute myeloid leukaemia in patients unsuitable for intensive chemotherapy and who have a bone marrow blast count >30% where the following criteria have been met
Treatment criterion (#10) updated